[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633257":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":39,"responsibleParty":56,"collaborators":25,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":25,"enrollmentInfo":69,"targetDuration":25,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":91,"whyStopped":25,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Montreal Heart Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Low-dose Aspirin Prescription","EXPERIMENTAL","Aspirin 81 mg orally once daily prescription",[13],"Drug: Prescription of Aspirin",{"label":15,"type":6,"description":16,"interventionNames":17},"No Prescription","No prescription of aspirin 81 mg orally once daily",[18],"Drug: No prescription",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Prescription of Aspirin","Aspirin 81 mg orally once daily",[9],null,{"type":21,"name":27,"description":16,"armGroupLabels":28,"otherNames":25},"No prescription",[15],[30,36],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},"Cyril Gagnon, MD","CONTACT","514-376-3330","2698","cyril.gagnon@umontreal.ca",{"name":37,"role":32,"phone":33,"phoneExt":34,"email":38},"Samara Bloom, MSc","samara.bloom@icm-mhi.org",[40],{"facility":5,"status":25,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Montreal","Quebec","H1T 1C8","Canada","CA",{"type":47,"coordinates":48},"Point",[49,50],-73.58781,45.50884,{"lat":50,"lon":49},[53],{"name":54,"role":32,"phone":33,"phoneExt":34,"email":55},"Samara Bloom, BSc, MSc","Samara.Bloom@icm-mhi.org",{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Guillaume Marquis-Gravel","Principal Investigator","100633257","phase-3-aspirin-in-subclinical-coronary-artery-disease-a-pilot-randomised-controlled-trial-100633257",false,"NCT07524335","Aspirin in Subclinical Coronary Artery Disease: A Pilot Randomised Controlled Trial","ASCAD-P","Inclusion Criteria:\n\n1. Documented coronary atherosclerosis, as defined by one of the following criteria:\n\n   1. Coronary artery calcium (CAC) score \\> 0;\n   2. Cardiac CT angiography (CCTA) \u002F CoroScan: lesions \\\u003C70% in the right coronary (RCA), left anterior descending (LAD), and circumflex (Cx) arteries or their branches, and \\\u003C50% in the left main coronary artery;\n   3. Coronary angiography: lesions \\\u003C70% in the right coronary (RCA), left anterior descending (LAD), and circumflex (Cx) arteries or their branches, and \\\u003C50% in the left main coronary artery; if performed, physiological coronary assessments (FFR, dPR, iFR, etc.) and intracoronary imaging (IVUS or OCT) must be negative for significant disease.\n2. Willing and able to provide informed consent and comply with study procedures\n\nExclusion Criteria:\n\n1. History of myocardial infarction (MI), coronary revascularization, stroke, transient ischemic attack (TIA), or peripheral arterial revascularization procedure;\n2. Current prescription or clear indication for aspirin, low-molecular-weight heparin (LMWH), direct oral anticoagulants, or any other antithrombotic medication;\n3. Clear contraindication to aspirin;\n4. History of significant bleeding within the past year;\n5. Severe illness with limited life expectancy (i.e., \\\u003C5 years);\n6. Any condition that, in the investigator's judgment, would make participation unsafe for the patient.","ALL","40 Years",{"count":70,"type":71},48,"ESTIMATED","INTERVENTIONAL",[74],"PHASE3","In patients with subclinical coronary artery disease, the ASCAD-P study aims to assess the feasibility of a larger phase 3 pragmatic randomized controlled trial comparing prescription versus no prescription of low-dose aspirin in routine clinical practice.",[77,78],"Coronary Artery Disease","Subclinical Atherosclerotic Cardiovascular Disease",[80,81,82,83,84,85,86,87,88,89,90],"Pilot Study","Feasability Study","Randomized","Clinical Trial","Prospective","Pragmatic Trial","Aspirin","Coronary artery disease","Bleeding","Major Adverse Cardiovascular Events","Antiplatelet","NOT_YET_RECRUITING","2026-05-07",{"date":94,"type":95},"2026-05-12","ACTUAL",{"date":97,"type":71},"2026-05-01",{"date":99,"type":71},"2028-05-01",{"name":5,"class":6},1]